{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-002189","form_type":"8-K","ticker":"PTCT","cik":"0001070081","company_name":"PTC THERAPEUTICS, INC.","filed_at":"2024-02-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.285727+00:00","generated_at":"2026-06-05T06:07:20.657446+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"PTC Therapeutics 2023 revenue up 34% to $938M; guides 2024 revenue $600-680M","bullets":["Total revenue $937.8M (+34% YoY); net loss $626.6M vs $559.0M in 2022.","DMD franchise: Translarna $356M, Emflaza $255M; Evrysdi royalty + milestone $268.9M.","Cash and securities $876.7M vs $410.7M a year ago; debt extinguishment loss $137.6M.","Pipeline: sepiapterin MAA submission in Mar 2024, NDA by Q3 2024; vatiquinone NDA expected late 2024.","2024 guidance: total revenue $600-680M (down from $938M); GAAP R&D+SG&A $740-835M."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-002189","json":"https://secwatch.observer/filing/0001558370-24-002189.json","markdown":"https://secwatch.observer/filing/0001558370-24-002189.md","text":"https://secwatch.observer/filing/0001558370-24-002189.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070081/000155837024002189/0001558370-24-002189-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070081/000155837024002189/tmb-20240229x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T06:07:20.657446+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b0dc24f7719d09f3ae877b8fe5ef375f80aae16d","claim":"PTC THERAPEUTICS, INC. reported the fourth quarter and full year ended December 31, 2023 results: revenue Total revenue was $307.1 million for the fourth quarter of 2023... Total revenue was $937.8 million for full year 2023.","evidence_excerpt":"PTC Therapeutics, Inc. (the “Company”) announced its financial results for the quarter and fiscal year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1070081/000155837024002189/0001558370-24-002189-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Revenue","value":"Total revenue was $307.1 million for the fourth quarter of 2023... Total revenue was $937.8 million for full year 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}